Estudo retrospectivo do tratamento de leucemia mielóide aguda com o transplante de medula óssea: a experiência brasileira

Abstract

compared to second (2CR) and other (p<0.0001), and longer OS in de novo AML than in secondary. In the alloBMT group we found more patients with advanced disease (60%), while in the autoBMT group, we found more M3 patients (24%), which could explain the difference in OS. Most of our results are in accordance with IBMTR data. One should consider the fact that this is a retrospective study and our findings should be analysed with caution. Rev. bras. hematol.

Pre-transplant arm muscle area: a simple measure to identify patients at risk

“…In addition, the underlying disease, the conditioning regimen, as well as the toxicity of the treatment, acute GVHD and chronic pulmonary complications may be related to mortality [35,36]. The incidence of acute GVHD increases when HSCT is performed with unrelated donor and the increase in the difference between the ages of donor and recipient.…”

Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia

“…Several studies, most of them not designed to test autologous vs. allogeneic HSCT for AML , have suggested the superiority of allogeneic SCT over autologous for AML consolidation. However, the Brazilian experience seems to suggest a role for autologous SCT as consolidation for AML . Of note, a recent study designed to compare autologous with allogeneic SCT and chemotherapy only, for the treatment of low‐risk AML, showed comparable results for auto‐ and allo‐SCT, both superior to chemotherapy only .…”

“…Whether the addition of further pretransplant chemotherapy for MDR‐positive patients will bring better overall results remains to be determined. For autologous HSCT, as mentioned above, in Brazil, at least one round of chemo consolidation therapy is recommended prior to transplant .…”

Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines

“…However, it is important to point out that in this study, the surviving patients and those in CR after 5 years included, though few in number, patients who had undergone allogeneic HSCT and patients in palliative care or untreated. However, in a retrospective study on the results of allogeneic and autologous HSCT for AML in Brazil (29) , there were no differences for overall survival (OS) between these two types of transplantations. Therefore, in Brazil, autologous HSCT is an accepted procedure of consolidation therapy for AML, after two rounds of induction and at least one round of consolidation therapy, for intermediate-risk patients without any HLA-compatible donor.…”